The social media company reports earnings on Wednesday. Shares in Novo Nordisk, the company behind weigh loss drug Wegovy, dropped almost 3% following a Reuters report that raised concerns about ...

Novo Nordisk will invest around $1 billion to expand its production site in Montes Claros, Brazil, marking one of the largest pharmaceutical investments in the nation’s history. The company’s ...

The merger of Novozymes and Chr. Hansen has created Novonesis, a global leader in what the new company calls “biosolutions.” Combining expertise, talent and research and development ...

Over the next 18 months, Novonesis will improve three of its local facilities to enhance its spore production capabilities. That’s spores as in plant spores. The city of Salem and the Salem ...

Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk. Trump Signs Executive Order To Change College Accreditation What is the most American-made car? Trump Shoots Down ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Novo Nordisk A/S (NVO) is a high-quality biopharma company that has been a growth play well before its recent obesity drug hit. Shares were hyped a while ago, but have now declined so much that ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other top falling stocks with unusual volume. Uncertainty around tariffs and macroeconomic ...

Swiss insurers Helvetia and Baloise to merge; shares up Novo Nordisk drops after positive trial results of Lilly's weight loss pill L'Oreal advances after reporting rise in Q1 sales April 22 ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value. Despite ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.